Kinnate Biopharma Inc. Common Stock
KNTE
KNTE was delisted on the 2nd of April, 2024.
72 hedge funds and large institutions have $121M invested in Kinnate Biopharma Inc. Common Stock in 2023 Q2 according to their latest regulatory filings, with 29 funds opening new positions, 12 increasing their positions, 23 reducing their positions, and 28 closing their positions.
1,100% more call options, than puts
Call options by funds: $72K | Put options by funds: $6K
1% more funds holding
Funds holding: 71 → 72 (+1)
4% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 28
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
48% less repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 23
55% less capital invested
Capital invested by funds: $270M → $121M (-$149M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$11M |
| 2 |
FCMV
Foresite Capital Management V
Larkspur,
California
|
+$5.98M |
| 3 |
Millennium Management
New York
|
+$3.48M |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
+$1.55M |
| 5 |
Renaissance Technologies
New York
|
+$876K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$26.7M |
| 2 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$7.25M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
-$6.81M |
| 4 |
BlackRock
New York
|
-$5.99M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$3.75M |
KNTE Hedge Fund Activity: Q2 2023 in Review
72 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in Kinnate Biopharma Inc. Common Stock (KNTE) for Q2 2023, worth a combined $121M — down 55% from $270M a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new KNTE positions and 28 closed out — a net gain of 1 holder — while 12 added to existing stakes and 23 trimmed.
The largest buyer was OrbiMed, adding an estimated $11M. The largest seller was RA Capital Management, exiting entirely with an estimated $26.7M sold.
- 72 institutional investors held Kinnate Biopharma Inc. Common Stock (KNTE) as of Q2 2023, up from 71 in Q1 2023.
- Funds reported $121M of Kinnate Biopharma Inc. Common Stock stock for Q2 2023, down 55% quarter-over-quarter.
- 29 funds opened new Kinnate Biopharma Inc. Common Stock positions in Q2 2023 and 28 closed out, a net change of +1 holder.
- The largest Kinnate Biopharma Inc. Common Stock buyer in Q2 2023 was OrbiMed, an estimated $11M added.
- The largest Kinnate Biopharma Inc. Common Stock seller in Q2 2023 was RA Capital Management, an estimated $26.7M sold.
Based on aggregated 13F filings for Q2 2023.